blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2328931

EP2328931 - ANTI-HEPCIDIN-25 SELECTIVE ANTIBODIES AND USES THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  20.06.2014
Database last updated on 02.09.2024
Most recent event   Tooltip22.06.2018Lapse of the patent in a contracting state
New state(s): MK		published on 25.07.2018  [2018/30]
Applicant(s)For all designated states
ELI LILLY AND COMPANY
Lilly Corporate Center
Indianapolis, IN 46285 / US
[2011/23]
Inventor(s)01 / LEUNG, Donmienne, Doen, Mun
Eli Lilly And Company
Lilly Corporate Center
Indianapolis, IN 46285 / US
02 / LUAN, Peng
1869 Altamont Circle
Livermore California 94551 / US
03 / TANG, Ying
Eli Lilly And Company
Lilly Corporate Center
Indianapolis, IN 46285 / US
04 / WITCHER, Derrick, Ryan
Eli Lilly And Company
Lilly Corporate Center
Indianapolis, IN 46285 / US
05 / YACHI, Pia, Pauliina
Eli Lilly And Company
Lilly Corporate Center
Indianapolis, IN 46285 / US
 [2013/33]
Former [2011/27]01 / LEUNG, Donmienne, Doen, Mun
Eli Lilly And Company Lilly Corporate Center
Indianapolis, IN 46285 / US
02 / LUAN, Peng
1869 Altamont Circle
Livermore California 94551 / US
03 / TANG, Ying
Eli Lilly And Company Lilly Corporate Center
Indianapolis, IN 46285 / US
04 / WITCHER, Derrick, Ryan
Eli Lilly And Company Lilly Corporate Center
Indianapolis, IN 46285 / US
05 / YACHI, Pia, Pauliina
Eli Lilly And Company Lilly Corporate Center
Indianapolis, IN 46285 / US
Former [2011/23]01 / LEUNG, Donmienne, Doen, Mun
Eli Lilly And Company Lilly Corporate Center
Indianapolis, IN 46285 / US
02 / LUAN, Peng
Eli Lilly And Company Lilly Corporate Center
Indianapolis, IN 46285 / US
03 / TANG, Ying
Eli Lilly And Company Lilly Corporate Center
Indianapolis, IN 46285 / US
04 / WITCHER, Derrick, Ryan
Eli Lilly And Company Lilly Corporate Center
Indianapolis, IN 46285 / US
05 / YACHI, Pia, Pauliina
Eli Lilly And Company Lilly Corporate Center
Indianapolis, IN 46285 / US
Representative(s)O'Connor, David, et al
Eli Lilly and Company Limited
Lilly research Centre
Erl Wood Manor
Windlesham, Surrey GU20 6PH / GB
[2013/08]
Former [2012/03]Burnside, Ivan John, et al
Eli Lilly and Company Limited Lilly Research Centre Erl Wood Manor Sunninghill Road Windlesham
Surrey GU20 6PH / GB
Former [2011/23]Commander, Paul Martin Brial
Eli Lilly and Company Limited Lilly Research Centre Erl Wood Manor Sunninghill Road
GB-Windlesham, Surrey GU20 6PH / GB
Application number, filing date09790908.929.07.2009
[2011/23]
WO2009US52044
Priority number, dateUS20080086557P06.08.2008         Original published format: US 86557 P
[2011/23]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2010017070
Date:11.02.2010
Language:EN
[2010/06]
Type: A1 Application with search report 
No.:EP2328931
Date:08.06.2011
Language:EN
The application published by WIPO in one of the EPO official languages on 11.02.2010 takes the place of the publication of the European patent application.
[2011/23]
Type: B1 Patent specification 
No.:EP2328931
Date:14.08.2013
Language:EN
[2013/33]
Search report(s)International search report - published on:EP11.02.2010
ClassificationIPC:C07K16/26, G01N33/577, A61K39/395, A61P7/06
[2011/23]
CPC:
C07K16/26 (EP,US); C07K16/18 (KR); A61K39/395 (KR);
A61P7/06 (EP); G01N33/577 (KR); G01N33/74 (EP,US);
C07K2317/34 (EP,US); C07K2317/565 (EP,US); C07K2317/567 (EP,US);
C07K2317/92 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2011/23]
Extension statesAL07.03.2011
BA07.03.2011
RS07.03.2011
TitleGerman:SELEKTIVE ANTI-HEPCIDIN-25-ANTIKÖRPER UND ANWENDUNGEN DAVON[2011/23]
English:ANTI-HEPCIDIN-25 SELECTIVE ANTIBODIES AND USES THEREOF[2011/23]
French:ANTICORPS SÉLECTIFS ANTI-HEPCIDINE-25 ET LEURS UTILISATIONS[2011/23]
Entry into regional phase07.03.2011National basic fee paid 
07.03.2011Designation fee(s) paid 
07.03.2011Examination fee paid 
Examination procedure07.03.2011Examination requested  [2011/23]
07.04.2011Amendment by applicant (claims and/or description)
26.10.2011Despatch of a communication from the examining division (Time limit: M04)
01.03.2012Reply to a communication from the examining division
04.03.2013Communication of intention to grant the patent
28.06.2013Fee for grant paid
28.06.2013Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  26.10.2011
Opposition(s)15.05.2014No opposition filed within time limit [2014/30]
Fees paidRenewal fee
16.07.2011Renewal fee patent year 03
10.07.2012Renewal fee patent year 04
28.06.2013Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU29.07.2009
BG14.08.2013
CY14.08.2013
CZ14.08.2013
EE14.08.2013
HR14.08.2013
LT14.08.2013
LV14.08.2013
MC14.08.2013
MK14.08.2013
MT14.08.2013
RO14.08.2013
SI14.08.2013
SK14.08.2013
SM14.08.2013
IS14.12.2013
[2018/30]
Former [2016/32]HU29.07.2009
BG14.08.2013
CY14.08.2013
CZ14.08.2013
EE14.08.2013
HR14.08.2013
LT14.08.2013
LV14.08.2013
MC14.08.2013
MT14.08.2013
RO14.08.2013
SI14.08.2013
SK14.08.2013
SM14.08.2013
IS14.12.2013
Former [2016/28]BG14.08.2013
CY14.08.2013
CZ14.08.2013
EE14.08.2013
HR14.08.2013
LT14.08.2013
LV14.08.2013
MC14.08.2013
MT14.08.2013
RO14.08.2013
SI14.08.2013
SK14.08.2013
SM14.08.2013
IS14.12.2013
Former [2016/22]CY14.08.2013
CZ14.08.2013
EE14.08.2013
HR14.08.2013
LT14.08.2013
LV14.08.2013
MC14.08.2013
RO14.08.2013
SI14.08.2013
SK14.08.2013
SM14.08.2013
IS14.12.2013
Former [2016/21]CY14.08.2013
CZ14.08.2013
EE14.08.2013
HR14.08.2013
LT14.08.2013
LV14.08.2013
MC14.08.2013
RO14.08.2013
SI14.08.2013
SK14.08.2013
IS14.12.2013
Former [2014/23]CY14.08.2013
CZ14.08.2013
EE14.08.2013
HR14.08.2013
LT14.08.2013
LV14.08.2013
RO14.08.2013
SI14.08.2013
SK14.08.2013
IS14.12.2013
Former [2014/22]CY14.08.2013
HR14.08.2013
LT14.08.2013
LV14.08.2013
RO14.08.2013
SI14.08.2013
IS14.12.2013
Former [2014/18]CY14.08.2013
HR14.08.2013
LT14.08.2013
LV14.08.2013
SI14.08.2013
IS14.12.2013
Former [2014/12]CY17.07.2013
HR14.08.2013
LT14.08.2013
LV14.08.2013
SI14.08.2013
IS14.12.2013
Former [2014/10]CY17.07.2013
HR14.08.2013
LT14.08.2013
IS14.12.2013
Former [2014/09]HR14.08.2013
LT14.08.2013
Former [2014/08]LT14.08.2013
Cited inInternational search[XA]US2006019339  (LAUTH XAVIER [US], et al) [X] 1-6,9-10,12-19,31 * paragraph [0094] - paragraph [0097]; claims 8-20 * [A] 7-8,11,20-30;
 [X]US2007224186  (KULAKSIZ HASAN [DE], et al) [X] 1-6,9-10 * page 78; claims 1-23 *;
 [XPI]WO2008097461  (AMGEN INC [US], et al) [XP] 1-6,9-10,12-22,28-31 * paragraph [0408]; examples 10-20,30-32; tables 3,6,7 * [I] 7-8,11,23-27;
 [IP]WO2009027752  (HELLENIC PASTEUR INST [GR], et al) [IP] 1-31 * page 26, line 17 - page 27, line l; claims 23-27 *;
 [XPI]WO2009044284  (INST NAT SANTE RECH MED [FR], et al) [XP] 1-6,9-10,12-22,28-31 * page 11; examples 1-3; claims 1-5,12-14 * [I] 7-8,11,23-27;
 [XPI]WO2009058797  (LILLY CO ELI [US], et al) [XP] 1-6,9-10,12-22,28-31 * examples 2-6; claims 1-44; tables 5,6,9 * [I] 7-8,11,23-27;
 [A]  - KEMNA ERWIN H J M ET AL, "Hepcidin: from discovery to differential diagnosis", HAEMATOLOGICA, FONDAZIONE FERRATA STORTI, ROME, IT, (20080101), vol. 93, no. 1, ISSN 0390-6078, pages 90 - 97, XP002502643 [A] 1-31 * the whole document *

DOI:   http://dx.doi.org/10.3324/HAEMATOL.11705
by applicantWO2005005604
 US2006019339
 US2007224186
 US2008213277
    - KEMNA, E.H. ET AL., HAEMATOLOGICA, (2008), vol. 93, no. 1, pages 90 - 97
    - ROE M.A. ET AL., BR J NUTR., (2007), vol. 97, pages 544 - 549
    - LUUKKONEN S.; PUNNONEN K., CLIN CHEM LAB MED., (2006), vol. 44, pages 1361 - 1362
    - GUTIERREZ, J.A. ET AL., BIOTECHNIQUES, (2005), vol. 38, pages S13 - S17
    - MURPHY ET AL., BLOOD, (2007), vol. 110, pages 1048 - 1054
    - KEMNA, E.H. ET AL., CLIN. CHEM., (2007), vol. 53, pages 620 - 628
    - PLUCKTHUN, The Pharmacology of Monoclonal Antibodies, SPRINGER-VERLAG, (1994), vol. 113, pages 269 - 315
    - JAYASENA, S.D., CLIN. CHEM., (1999), vol. 45, pages 1628 - 1650
    - FELLOUSE, F.A. ET AL., J. MOL. BIOL., (2007), vol. 373, no. 4, pages 924 - 940
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.